- Home
- MAIA vs ALGS Comparison
MAIA vs ALGS Comparison
Compare MAIA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | ALGS |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 49.7M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAIA | ALGS |
|---|---|---|
| Price | $2.08 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | ★ 551.5K | 39.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,611,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $3.76 |
| 52 Week High | $3.19 | $14.52 |
Technical Indicators
Market Signals| Indicator | MAIA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 42.88 |
| Support Level | $1.61 | $6.18 |
| Resistance Level | $3.19 | $8.84 |
| Average True Range (ATR) | 0.21 | 0.58 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 51.95 | 41.18 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.